For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, which is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Common side effects include abdominal pain, vomiting, diarrhea, weakness, and rashes. Other severe side effects include blood clotting problems, allergic reactions, heart problems, and low blood cell counts. It is not recommended in people with kidney problems. Use during pregnancy may result in harm to the baby. Capecitabine, inside the body, is converted to 5-fluorouracil (5-FU) through which it acts. It belongs to the class of medications known as fluoropyrimidines, which also includes 5-fluorouracil and tegafur.
LPI (LP Information)' newest research report, the "Capecitabine Industry Forecast" looks at past sales and reviews total world Capecitabine sales in 2022, providing a comprehensive analysis by region and market sector of projected Capecitabine sales for 2023 through 2029. With Capecitabine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Capecitabine industry.
This Insight Report provides a comprehensive analysis of the global Capecitabine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Capecitabine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Capecitabine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Capecitabine and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Capecitabine.
The global Capecitabine market size is projected to grow from US$ 1003.9 million in 2022 to US$ 975.1 million in 2029; it is expected to grow at a CAGR of 975.1 from 2023 to 2029.
Roche, Teva and Mylan are the top 3 of Capecitabine, with about 87% market shares.
This report presents a comprehensive overview, market shares, and growth opportunities of Capecitabine market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
- 500 mg
- 150 mg
Segmentation by application
- Breast Cancer
- Colorectal Cancer
- Stomach Cancer
This report also splits the market by region:
- Americas
- - United States
- - Canada
- - Mexico
- - Brazil
- APAC
- - China
- - Japan
- - Korea
- - Southeast Asia
- - India
- - Australia
- Europe
- - Germany
- - France
- - UK
- - Italy
- - Russia
- Middle East & Africa
- - Egypt
- - South Africa
- - Israel
- - Turkey
- - GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
- Roche
- Teva
- Mylan
- Hikma
- Hengrui Medicine
- Cipla
- Reliance Group
- Hetero
Key Questions Addressed in this Report
What is the 10-year outlook for the global Capecitabine market?
What factors are driving Capecitabine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Capecitabine market opportunities vary by end market size?
How does Capecitabine break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?